OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Grigg on the Future Treatment Landscape of Renal Cell Carcinoma

October 30th 2018

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses the future treatment landscape of renal cell carcinoma (RCC).

Dr. Kearns on Choosing Treatment for Patients With Prostate Cancer

October 30th 2018

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses factors to consider when choosing treatment for a patient with prostate cancer.

Dr. Cercek on Induction Chemotherapy in Mismatch Repair Deficient Rectal Cancer

October 29th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

Dr. O'Regan Discusses Biosimilar Education in Oncology

October 29th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biosimilar education in oncology.

Dr. Tasian on the Heterogeneity of Ph-Like ALL in Pediatric Patients

October 29th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the heterogeneity of pediatric Philadelphia (Ph)-like acute lymphoblastic leukemia.

Dr. Patel on Skepticism Associated With Biosimilars

October 29th 2018

Kashyap Patel, MD, president, Carolina Blood and Cancer Center, medical director, International Oncology Network, discusses skepticism associated with biosimilars in oncology.

Dr. Cohen on the Potential of BTK Inhibitors in Frontline Treatment of MCL

October 27th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the potential of Bruton tyrosine kinase (BTK) inhibitors in the frontline treatment of patients with mantle cell lymphoma (MCL).

Dr. Chien on De-Escalation Strategies for Patients With HER2-Positive Breast Cancer

October 27th 2018

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.

Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars

October 27th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses a comparative review of trastuzumab (Herceptin) biosimilars.

Dr. Kahl on Patient Preference in Treatment Selection for CLL

October 27th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses patient preference in treatment selection for chronic lymphocytic leukemia.

Dr. Karam on Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer

October 27th 2018

Amer Karam, MD, associate clinical professor, Gynecologic Oncology, Stanford Hospital, director, Robotic Surgery and Outreach, Division of Gynecologic Oncology, Stanford Medicine, discusses primary debulking surgery versus neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Dr. Makker Discusses Immunogenicity in Endometrial Cancer

October 27th 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunogenicity in endometrial cancer.

Dr. Clark on the Potential of Immunotherapy in Renal Cell Carcinoma

October 26th 2018

Peter Clark, MD, medical oncologist, Levine Cancer Institute, discusses the potential of immunotherapy in the treatment of patients with renal cell carcinoma (RCC).

Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC

October 25th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

Dr. Weise Discusses Challenges With Biosimilar Acceptance in Oncology

October 25th 2018

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

Dr. Rischin Discusses Cemiplimab in Cervical Cancer

October 25th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the use of cemiplimab (Libtayo) in patients with cervical cancer.

Dr. Sweis on Immunotherapy Combinations in Kidney Cancer

October 25th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Dr. Weber on Discontinuing Immunotherapy in Melanoma

October 25th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

Dr. Schroeder on Tolerability of Treatment For Myeloma

October 25th 2018

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

Dr. Amin on Next Steps With Immunotherapy in Advanced RCC

October 24th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.